Why did Eli Lilly and Company move?
Written after the close on
Eli Lilly fell slightly as obesity-drug competition stayed in focus. Over the last five trading days Eli Lilly fell sharply, in line with a sharply weaker healthcare sector while the broad market was roughly flat; the drop likely reflects profit-taking after a long run and jitters about competition in weight-loss drugs, partly offset by fresh trial data for its obesity and diabetes candidates and an expanded U.S. approval for its blood-cancer drug Jaypirca. The last session's modest decline came as the wider market rose, suggesting company-specific caution rather than a sector-wide move. Watch the late-October earnings report for updates on revenue expectations and pricing pressure.
Earlier days
Eli Lilly fell as obesity-trial wins met a pipeline setback. Over the last five trading days Eli Lilly fell clearly, a bigger drop than the slightly lower broad market and in line with a clearly weaker healthcare sector. The likely driver was the end of its collaboration with Foghorn Therapeutics, which said it will not advance their joint cancer programs and will cut about 40% of its staff — a reminder that not every partnership pans out. That partly offset positive news, including strong late-stage results for the obesity and diabetes candidates EloraTZP and retatrutide (a triple agonist is a drug hitting three hormone targets at once) and a fresh US approval for its once-weekly insulin. Watch the late-October earnings report, where investors will weigh whether the metabolic franchise keeps growing fast enough to justify its valuation.
Eli Lilly edges up as pipeline news offsets a soft market. Eli Lilly and Company (LLY on NYSE) rose slightly over the last five trading days, moving against a clearly weaker S&P 500 and ahead of a slightly higher healthcare sector, with the latest session roughly flat. Management also signalled it is hunting larger deals in infectious disease, women's health and mental health, and a research pact with InnoCare Pharma could add up to five new medicines — all of which keeps the growth story intact even as rival obesity data from Roche and Viking Therapeutics circulates. Watch the next earnings report in late October, when the raised full-year revenue guidance of $85–87 billion and the pipeline, including orforglipron for type 2 diabetes, will be tested.
Open Eli Lilly and Company's chart
More companies
History in plain words, not investment advice.